Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401647 · ClinicalTrials.gov registry record · Phase 3
Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia
A Phase 3 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,024
- Enrollment target
NCT01401647 is a Phase 3 study that has completed, run by University of Washington. The registered enrollment target is 3,024 participants.
The verdict
NCT01401647, a Phase 3 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,024 participants
- Enrollment target
Study Summary
The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
Interventions
- DRUG Lidocaine
- OTHER Normal saline
- DRUG amiodarone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,024 participants |
| Start Date | 2012-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01401647
The ClinicalTrials.gov registry entry for NCT01401647 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,024 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lidocaine is the first listed.
NCT01401647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01401647 about?
NCT01401647 is a clinical study titled "Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia". The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
What is the current status of trial NCT01401647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,024 participants. The study started on 2012-05. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01401647?
The interventions under investigation include: Lidocaine (DRUG), Normal saline (OTHER), amiodarone (DRUG).
Who is sponsoring clinical trial NCT01401647?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.